Trius Therapeutics, Inc.

San Diego, CA 92121

Market Performance

NASDAQ: TSRX
52 Week Low $N/A

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $4.29MM
First Award Date 05/02/04
Most Recent Award Date 08/01/07

Key Personnel

Last Name Name Awards Contact
Haselbeck Robert J Haselbeck 3
Stidham Mark Alan Stidham 2
Finn John M Finn 1

6 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 08/01/07 - 07/31/08

DESCRIPTION (provided by applicant): There is an urgent need for new classes of antibiotics effective on Bacillus anthracis. The ideal drug to address this need would be a small molecule that acts through inhibition of a novel bacterial-specific target. We have discovered a new class of small molecule inhibitors of MurB the second enzyme in bact...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 08/15/06 - 07/31/07

DESCRIPTION (provided by applicant): There is an urgent need for new classes of antibiotics effective on Bacillus anthracis. The ideal drug to address this need would be a small molecule that acts through inhibition of a novel bacterial-specific target. We have discovered a new class of small molecule inhibitors of MurB the second enzyme in bact...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 07/15/06 - 07/14/07

DESCRIPTION (provided by applicant): The emergence of bacterial strains resistant to most of the current antibacterial agents has a significant negative impact on public health. To combat bacterial resistance, new classes of antibacterial agents are needed that have expanded spectrum that includes the resistant strains. Particularly attractive a...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/06 - 04/30/07

DESCRIPTION (provided by investigator): New therapeutics are urgently needed to treat infections caused by drug-resistant variants of bacterial pathogens, particularly pathogens likely to be utilized as weapons of terrorism or biological warfare. The objective of the proposed work is to discover and develop new therapeutics for treatment of inf...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/05 - 04/30/06

DESCRIPTION (provided by investigator): New therapeutics are urgently needed to treat infections caused by drug-resistant variants of bacterial pathogens, particularly pathogens likely to be utilized as weapons of terrorism or biological warfare. The objective of the proposed work is to discover and develop new therapeutics for treatment of inf...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/02/04 - 04/30/05

DESCRIPTION (provided by investigator): New therapeutics are urgently needed to treat infections caused by drug-resistant variants of bacterial pathogens, particularly pathogens likely to be utilized as weapons of terrorism or biological warfare. The objective of the proposed work is to discover and develop new therapeutics for treatment of inf...